UY33818A - Nueva composicion farmaceutica - Google Patents

Nueva composicion farmaceutica

Info

Publication number
UY33818A
UY33818A UY0001033818A UY33818A UY33818A UY 33818 A UY33818 A UY 33818A UY 0001033818 A UY0001033818 A UY 0001033818A UY 33818 A UY33818 A UY 33818A UY 33818 A UY33818 A UY 33818A
Authority
UY
Uruguay
Prior art keywords
new pharmaceutical
pharmaceutical composition
dimethyl
trioxo
pyrido
Prior art date
Application number
UY0001033818A
Other languages
English (en)
Spanish (es)
Inventor
Douglas J Demarini
Henriquez Francisco
Wang Lihong
Ngocdiep T Le
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33818(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of UY33818A publication Critical patent/UY33818A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY0001033818A 2010-12-20 2011-12-19 Nueva composicion farmaceutica UY33818A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
UY33818A true UY33818A (es) 2012-07-31

Family

ID=46314827

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033818A UY33818A (es) 2010-12-20 2011-12-19 Nueva composicion farmaceutica

Country Status (38)

Country Link
US (5) US20130266649A1 (enExample)
EP (4) EP2654736B1 (enExample)
JP (2) JP6126014B2 (enExample)
KR (1) KR101911109B1 (enExample)
CN (1) CN103998041B (enExample)
AR (2) AR084102A1 (enExample)
AU (1) AU2011349422B2 (enExample)
BR (1) BR112013015602B1 (enExample)
CA (1) CA2822701C (enExample)
CL (1) CL2013001779A1 (enExample)
CR (1) CR20130352A (enExample)
CY (1) CY1123376T1 (enExample)
DK (3) DK4159205T3 (enExample)
DO (1) DOP2013000138A (enExample)
EA (1) EA025198B1 (enExample)
ES (3) ES2985024T3 (enExample)
FI (2) FI4159205T3 (enExample)
HR (3) HRP20240563T1 (enExample)
HU (3) HUE066526T2 (enExample)
IL (1) IL226855A (enExample)
JO (1) JO3594B1 (enExample)
LT (3) LT4159204T (enExample)
MA (1) MA34883B1 (enExample)
MX (1) MX2013007073A (enExample)
MY (1) MY170501A (enExample)
NZ (1) NZ612157A (enExample)
PE (1) PE20140040A1 (enExample)
PH (1) PH12013501209A1 (enExample)
PL (3) PL4159205T3 (enExample)
PT (3) PT4159204T (enExample)
RS (2) RS65497B1 (enExample)
SG (1) SG191054A1 (enExample)
SI (3) SI4159205T1 (enExample)
TW (1) TWI505828B (enExample)
UA (1) UA113158C2 (enExample)
UY (1) UY33818A (enExample)
WO (1) WO2012088033A2 (enExample)
ZA (1) ZA201304189B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
BR112015003418A2 (pt) 2012-08-17 2017-07-04 Hoffmann La Roche produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica.
AU2013352369B2 (en) * 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1(2H)-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
PL3496722T3 (pl) * 2016-08-10 2025-11-12 F. Hoffmann-La Roche Ag Kompozycje farmaceutyczne zawierające inhibitory kinazy białkowej Akt
RU2627692C1 (ru) 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
TW201818936A (zh) 2016-11-25 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物醫藥組成物及其製備方法
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JP2022540253A (ja) * 2019-07-11 2022-09-14 プラクシス プレシジョン メディシンズ, インコーポレイテッド T型カルシウムチャネル調節因子の製剤およびその使用方法
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
RU2364596C2 (ru) * 2004-06-11 2009-08-20 Джапан Тобакко Инк. ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
WO2008060890A2 (en) * 2006-11-09 2008-05-22 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EP2175885B1 (en) * 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
US8414918B2 (en) * 2007-09-25 2013-04-09 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
KR20110031370A (ko) 2008-07-08 2011-03-25 베타 파마, 인크. 염산 icotinib, 합성, 결정형, 약학적 조성물 및 이의 사용
AU2010298280B2 (en) 2009-09-23 2014-07-03 Novartis Ag Combination
EA021951B1 (ru) 2009-09-23 2015-10-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Противораковая комбинация
EA201270475A1 (ru) 2009-09-28 2012-11-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинация
RS65800B1 (sr) * 2009-10-16 2024-08-30 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
EP2501379B1 (en) 2009-11-17 2016-03-23 Novartis AG Combination
US20130165456A1 (en) 2010-08-26 2013-06-27 Tona M. Gilmer Combination
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu

Also Published As

Publication number Publication date
LT4159205T (lt) 2024-05-10
LT2654736T (lt) 2020-09-25
CN103998041A (zh) 2014-08-20
KR101911109B1 (ko) 2018-10-23
WO2012088033A3 (en) 2014-03-13
PT4159204T (pt) 2024-05-07
FI4159205T3 (fi) 2024-04-23
CN103998041B (zh) 2016-08-17
US8580304B2 (en) 2013-11-12
HRP20201409T1 (hr) 2020-11-27
BR112013015602A2 (pt) 2017-02-21
SG191054A1 (en) 2013-08-30
DK2654736T3 (da) 2020-09-14
EA201390913A1 (ru) 2014-04-30
HRP20240564T1 (hr) 2024-09-27
JO3594B1 (ar) 2020-07-05
BR112013015602B1 (pt) 2022-03-03
US9399021B2 (en) 2016-07-26
FI4159204T3 (fi) 2024-04-22
DK4159205T3 (da) 2024-05-13
IL226855A (en) 2017-04-30
TWI505828B (zh) 2015-11-01
DOP2013000138A (es) 2013-11-30
HUE050788T2 (hu) 2021-01-28
LT4159204T (lt) 2024-05-10
CA2822701C (en) 2018-10-23
US20120183613A1 (en) 2012-07-19
RS65497B1 (sr) 2024-06-28
HUE066526T2 (hu) 2024-08-28
HUE066525T2 (hu) 2024-08-28
EP4159205B1 (en) 2024-02-14
NZ612157A (en) 2015-05-29
US20140154316A1 (en) 2014-06-05
ES2982775T3 (es) 2024-10-17
ES2985024T3 (es) 2024-11-04
UA113158C2 (xx) 2016-12-26
EP2654736A4 (en) 2015-04-22
PT2654736T (pt) 2020-09-24
PL4159205T3 (pl) 2024-06-24
JP6126014B2 (ja) 2017-05-10
HRP20240563T1 (hr) 2024-08-16
CA2822701A1 (en) 2012-06-28
PE20140040A1 (es) 2014-02-26
MY170501A (en) 2019-08-08
WO2012088033A2 (en) 2012-06-28
SI4159204T1 (sl) 2024-06-28
EA025198B1 (ru) 2016-11-30
CL2013001779A1 (es) 2014-06-27
ZA201304189B (en) 2014-02-26
MA34883B1 (fr) 2014-02-01
US20140099365A1 (en) 2014-04-10
SI4159205T1 (sl) 2024-06-28
EP4159204B1 (en) 2024-02-14
AU2011349422B2 (en) 2015-12-10
EP4159205A1 (en) 2023-04-05
EP3808343A1 (en) 2021-04-21
PT4159205T (pt) 2024-05-08
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
KR20130130028A (ko) 2013-11-29
US9271941B2 (en) 2016-03-01
AU2011349422A1 (en) 2013-05-02
CY1123376T1 (el) 2021-12-31
SI2654736T1 (sl) 2020-10-30
US9155706B2 (en) 2015-10-13
US20130266649A1 (en) 2013-10-10
US20140037726A1 (en) 2014-02-06
ES2820536T3 (es) 2021-04-21
JP2014510704A (ja) 2014-05-01
PL2654736T3 (pl) 2020-12-14
CR20130352A (es) 2013-12-18
MX2013007073A (es) 2013-09-26
JP2017137299A (ja) 2017-08-10
EP2654736A2 (en) 2013-10-30
AR084102A1 (es) 2013-04-24
PL4159204T3 (pl) 2024-07-01
AR122185A2 (es) 2022-08-24
RS65496B1 (sr) 2024-06-28
PH12013501209A1 (en) 2013-07-29
EP4159204A1 (en) 2023-04-05
TW201249441A (en) 2012-12-16

Similar Documents

Publication Publication Date Title
DOP2013000138A (es) Nueva composición farmacéutica
UY35157A (es) Nueva composición farmacéutica conteniendo dimetilsulfóxido
CL2020000031A1 (es) Aparatos y métodos de cribas moldeadas por inyección. (divisional solicitud 201801786).
CL2014000821A1 (es) Compuestos derivados de 1h-pirazolo[4,3-c]quinolin-4(5h)-ona, inhibidores de la fosfodiestera 9 (pde9); composicion farmaceutica que los comprende; y agente para mejorar la alteracion cognitiva en la enfermedad de alzheimer.
BR112014001050A2 (pt) copolímero em bloco de poliéster poliamida, método para a preparação do mesmo, composição, produtos de liberação controlada e de cuidado pessoal, e, método para preparação de uma composição de gel
NI201200072A (es) Métodos y composiciones para tratar cáncer
UY34669A (es) COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
HK1208353A1 (en) Solid dosage form
BR112013013930A2 (pt) método para criar um produto de sementes misturadas de alta precisão, método para fazer a separação entre dois ou mais grupos de sementes e um produto de mistura de sementes
UY30307A1 (es) Moduladores de mglur5 vi
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
UY34031A (es) Componente de éster aromático en la formulación de composiciones agroquímicas
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
CO6781490A2 (es) Nueva composición farmacéutica
EP3031441A4 (en) Curable calcium phosphate composition for in vivo hard tissue repair, bone repair material, and various dental materials
CO7160058A2 (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
CU20100087A7 (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrófilos
FR2987265B1 (fr) Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application
UY34703A (es) Ciclobutilcarboxamidas, proceso para su preparación, composiciones pesticidas y composiciones farmacéuticas que las comprenden, y usos de las mismas como nematicidas
CN302266880S (zh) 戒指(aurore)

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211104

110 Patent granted

Effective date: 20221019